Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
51,567,377
-
Share change
-
+1,525,379
-
Total reported value
-
$3,257,869,910
-
Put/Call ratio
-
55%
-
Price per share
-
$63.22
-
Number of holders
-
225
-
Value change
-
+$120,748,445
-
Number of buys
-
112
-
Number of sells
-
119
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q1 2022
As of 31 Mar 2022,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
225 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,567,377 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., Capital Research Global Investors, VANGUARD GROUP INC, Neuberger Berman Group LLC, STATE STREET CORP, FRANKLIN RESOURCES INC, Fisher Asset Management, LLC, LONDON CO OF VIRGINIA, and LGT CAPITAL PARTNERS LTD..
This page lists
225
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.